Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

GNAQ/GNA11 antagonist DYP688

An antagonist of guanine nucleotide-binding protein G(q) subunit alpha (GNAQ)/ guanine nucleotide-binding protein subunit alpha-11 (GNA11), with potential antineoplastic activity. Upon administration, GNAQ/GNA11 antagonist DYP688 inhibits the activity of GNAQ/GNA11 and prevents GNAQ/GNA11-mediated signaling. This may prevent proliferation in tumors overexpressing and/or harboring mutations of GNAQ/GNA11. GNAQ and GNA11 are involved in carcinogenesis and are mutated in certain melanomas.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	DYP 688 DYP-688 DYP688

GNAQ/GNA11 antagonist DYP688

Search NCI's Drug Dictionary